Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors

Zacks
Ouvrir sur Zacks
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.71, marking a -4.87% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.52%. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.

Prior to today's trading, shares of the company had lost 0.51% lagged the Medical sector's gain of 3.23% and was narrower than the S&P 500's loss of 1.21%.

Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on November 9, 2026. In that report, analysts expect Hims & Hers Health, Inc. to post earnings of $0.07 per share. This would mark year-over-year growth of 16.67%. In the meantime, our current consensus estimate forecasts the revenue to be $893.37 million, indicating a 49.15% growth compared to the corresponding quarter of the prior year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.79 per share and revenue of $3.22 billion. These totals would mark changes of -249.06% and +37.03%, respectively, from last year.

Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #3 (Hold).

The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 39% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research